Chunhua Dai, John T Walker, Alena Shostak, Yasir Bouchi, Greg Poffenberger, Nathaniel J Hart, David A Jacobson, M Wade Calcutt, Rita Bottino, Dale L Greiner, Leonard D Shultz, Owen P McGuinness, E Danielle Dean, Alvin C Powers
Selective inhibitors of sodium glucose cotransporter-2 (SGLT2) are widely used for the treatment of type 2 diabetes and act primarily to lower blood glucose by preventing glucose reabsorption in the kidney. However, it is controversial whether these agents also act on the pancreatic islet, specifically the α cell, to increase glucagon secretion. To determine the effects of SGLT2 on human islets, we analyzed SGLT2 expression and hormone secretion by human islets treated with the SGLT2 inhibitor dapagliflozin (DAPA) in vitro and in vivo...
August 1, 2020: Endocrinology